Disclosed are compounds for the selective labeling of cell-surface sugars in cancer cells. The compounds are activatable by triggers specific to cancer cells, and, when metabolized, label a cancer cell surface sugar with an azide chemical group. Facilitated by a click chemistry reaction, combination of the cell surface-expressed azide with a alkynyl-drug conjugate enables efficient targeted drug delivery to cancer cells with reduced toxicity. Also disclosed are compounds for delivering a drug to an azide-bearing cancer cell, and methods of treating cancer using the compounds.
Original languageEnglish (US)
U.S. patent number11299509
Filing date2/12/18
StatePublished - Apr 12 2022


Dive into the research topics of 'Trigger-activatable sugar conjugates for cancer-selective labeling and targeting'. Together they form a unique fingerprint.

Cite this